{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:08Z","timestamp":1794047468007,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Hyperleukocytosis in pediatric acute myeloid leukemia (AML) is associated with severe complications and an inferior outcome. We report results on patients with hyperleukocytosis included in the NOPHO-DBH AML 2012 study. We recommended immediate initiation of full-dose chemotherapy (etoposide monotherapy for 5 days as part of the first course), avoiding leukapheresis and prephase chemotherapy. Of 714 patients included in the NOPHO-DBH AML 2012 study, 122 (17.1%) had hyperleukocytosis, and 111 were treated according to the recommendations with etoposide upfront without preceding leukapheresis or prephase chemotherapy. The first dose was applied the same day as the AML diagnosis or the day after in 94%. Etoposide was administered via peripheral veins in 37% of patients without major complications. After initiation of etoposide the white blood cell counts on days 2-5 were 69%, 36%, 17% and 8%, respectively, of the pre-treatment level. On day 3, 81% of patients had a white blood cell count &lt;100 x109\/L. Five-year event-free and overall survival rates for all patients with hyperleukocytosis were 52.9% (95% confidence interval [95% CI]: 44.4-63.0) and 74.1% (95% CI: 66.4-82.6), compared to 64.9% (95% CI: 60.9-69.1) and 78.9% (95% CI: 75.4-82.4) for patients without hyperleukocytosis (P&lt;0.001 for event-free survival, P=0.1 overall survival). Six-week early mortality was 4.1% for all patients with hyperleukocytosis (2.7% for the 111 patients treated with etoposide upfront). We conclude that management of hyperleukocytosis in pediatric AML with immediate etoposide monotherapy without leukapheresis or prephase chemotherapy is feasible, safe and effective. The reduction in white blood cell count during the first days is comparable to the reported results of leukapheresis, and outcomes seem at least equivalent to therapies including leukapheresis. Based on our results, we advocate abandoning leukapheresis for hyperleukocytosis in pediatric AML. Instead, it is crucial to start induction chemotherapy as early as possible.<\/jats:p>","DOI":"10.3324\/haematol.2024.285285","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T04:16:46Z","timestamp":1715228206000},"page":"2873-2883","source":"Crossref","is-referenced-by-count":8,"title":["Management of hyperleukocytosis in pediatric acute myeloid leukemia using immediate chemotherapy without leukapheresis: results from the NOPHO-DBH AML 2012 protocol"],"prefix":"10.3324","volume":"109","author":[{"given":"Bernward","family":"Zeller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nira","family":"Arad-Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Cheuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"De Moerloose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M. Fernandez","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Hasle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Jahnukainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian Lovvik","family":"Juul-Dam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gertjan","family":"Kaspers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zanna","family":"Kovalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olafur G.","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgitte","family":"Lausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Munthe-Kaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrika Noren","family":"Nystrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefine","family":"Palle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramune","family":"Pasauliene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis J.","family":"Pronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kadri","family":"Saks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tierens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Abrahamsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,5,9]]},"reference":[{"key":"65680","doi-asserted-by":"crossref","unstructured":"Greenwood MJ, Seftel MD, Richardson C. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma. 2006; 47(7):1245-1252.","DOI":"10.1080\/10428190600572673"},{"key":"65681","doi-asserted-by":"crossref","unstructured":"Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987; 60(12):3071-3079.","DOI":"10.1002\/1097-0142(19871215)60:12<3071::AID-CNCR2820601235>3.0.CO;2-Y"},{"key":"65682","doi-asserted-by":"crossref","unstructured":"Hug V, Keating M, McCredie K, Hester J, Bodey GP, Freireich EJ. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer. 1983; 52(5):773-779.","DOI":"10.1002\/1097-0142(19830901)52:5<773::AID-CNCR2820520503>3.0.CO;2-X"},{"key":"65683","doi-asserted-by":"crossref","unstructured":"Lowe EJ, Pui CH, Hancock ML, Geiger TL, Khan RB, Sandlund JT. Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis. Pediatr Blood Cancer. 2005; 45(1):10-15.","DOI":"10.1002\/pbc.20178"},{"key":"65684","doi-asserted-by":"crossref","unstructured":"Bug G, Anargyrou K, Tonn T. Impact of leukapheresis on early death rate in adult acute myeloid leukemia presenting with hyperleukocytosis. Transfusion. 2007; 47(10):1843-1850.","DOI":"10.1111\/j.1537-2995.2007.01406.x"},{"key":"65685","doi-asserted-by":"crossref","unstructured":"Creutzig U, R\u00f6ssig C, Dworzak M. Exchange transfusion and leukapheresis in pediatric patients with AML with high risk of early death by bleeding and leukostasis. Pediatr Blood Cancer. 2016; 63(4):640-645.","DOI":"10.1002\/pbc.25855"},{"key":"65686","doi-asserted-by":"crossref","unstructured":"Oberoi S, Lehrnbecher T, Phillips B. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leuk Res. 2014; 38(4):460-468.","DOI":"10.1016\/j.leukres.2014.01.004"},{"key":"65687","doi-asserted-by":"crossref","unstructured":"Sung L, Aplenc R, Alonzo TA, Gerbing RB, Gamis AS. Predictors and short-term outcomes of hyperleukocytosis in children with acute myeloid leukemia: a report from the Children\u2019s Oncology Group. Haematologica. 2012; 97(11):1770-1773.","DOI":"10.3324\/haematol.2012.065490"},{"key":"65688","doi-asserted-by":"crossref","unstructured":"Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma. 2022; 63(8):1780-1791.","DOI":"10.1080\/10428194.2022.2056178"},{"key":"65689","doi-asserted-by":"crossref","unstructured":"R\u00f6llig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015; 125(21):3246-3252.","DOI":"10.1182\/blood-2014-10-551507"},{"key":"65690","doi-asserted-by":"crossref","unstructured":"Pastore F, Pastore A, Wittmann G, Hiddemann W, Spiekermann K. The role of therapeutic leukapheresis in hyperleukocytotic AML. PLoS One. 2014; 9(4):e95062.","DOI":"10.1371\/journal.pone.0095062"},{"key":"65691","doi-asserted-by":"crossref","unstructured":"Chen KH, Liu HC, Liang DC. Minimally early morbidity in children with acute myeloid leukemia and hyperleukocytosis treated with prompt chemotherapy without leukapheresis. J Formos Med Assoc. 2014; 113(11):833-838.","DOI":"10.1016\/j.jfma.2014.01.006"},{"key":"65692","doi-asserted-by":"crossref","unstructured":"Chang MC, Chen TY, Tang JL. Leukapheresis and cranial irradiation in patients with hyperleukocytic acute myeloid leukemia: no impact on early mortality and intracranial hemorrhage. Am J Hematol. 2007; 82(11):976-980.","DOI":"10.1002\/ajh.20939"},{"key":"65693","doi-asserted-by":"crossref","unstructured":"Zeller B, Glosli H, Forestier E. Hyperleucocytosis in paediatric acute myeloid leukaemia - the challenge of white blood cell counts above 200 x 10(9) \/l. The NOPHO experience 1984-2014. Br J Haematol. 2017; 178(3):448-456.","DOI":"10.1111\/bjh.14692"},{"key":"65694","doi-asserted-by":"crossref","unstructured":"Arad-Cohen N, Zeller B, Abrahamsson J. Supportive care in pediatric acute myeloid leukemia: expert-based recommendations of the NOPHO-DB-SHIP consortium. Expert Rev Anticancer Ther. 2022; 22(11):1183-1196.","DOI":"10.1080\/14737140.2022.2131544"},{"key":"65695","doi-asserted-by":"crossref","unstructured":"Tierens A, Arad-Cohen NC, Cheuk D. Mitoxantrone versus liposomal daunorubicin in induction of pediatric AML with risk stratification based on flow cytometry measurement of residual disease. J Clin Oncol. 2024; 42(18):2174-2185.","DOI":"10.1200\/JCO.23.01841"},{"key":"65696","doi-asserted-by":"crossref","unstructured":"Tsukimoto I, Tawa A, Horibe K. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009; 27(24):4007-4013.","DOI":"10.1200\/JCO.2008.18.7948"},{"key":"65697","doi-asserted-by":"crossref","unstructured":"Link CL. Confidence intervals for the survival function using Cox\u2019s proportional-hazard model with covariates. Biometrics. 1984; 40(3):601-609.","DOI":"10.2307\/2530904"},{"key":"65698","doi-asserted-by":"crossref","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94(446):496-509.","DOI":"10.1080\/01621459.1999.10474144"},{"key":"65699","doi-asserted-by":"crossref","unstructured":"Abla O, Angelini P, Di Giuseppe G. Early complications of hyperleukocytosis and leukapheresis in childhood acute leukemias. J Pediatr Hematol Oncol. 2016; 38(2):111-117.","DOI":"10.1097\/MPH.0000000000000490"},{"key":"65700","doi-asserted-by":"crossref","unstructured":"Bruserud \u00d8, Liseth K, Stamnesfet S. Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfus Med. 2013; 23(6):397-406.","DOI":"10.1111\/tme.12067"},{"key":"65701","doi-asserted-by":"crossref","unstructured":"Bunin NJ, Pui CH. Differing complications of hyperleukocytosis in children with acute lymphoblastic or acute nonlymphoblastic leukemia. J Clin Oncol. 1985; 3(12):1590-1595.","DOI":"10.1200\/JCO.1985.3.12.1590"},{"key":"65702","doi-asserted-by":"crossref","unstructured":"Gr\u00e8ze V, Chambon F, Merlin E. Leukapheresis in management of hyperleukocytosis in children\u2019s leukemias. J Pediatr Hematol Oncol. 2014; 36(8):e513-517.","DOI":"10.1097\/MPH.0000000000000207"},{"key":"65703","doi-asserted-by":"crossref","unstructured":"Haase R, Merkel N, Diwan O, Elsner K, Kramm CM. Leukapheresis and exchange transfusion in children with acute leukemia and hyperleukocytosis. A single center experience. Klin Padiatr. 2009; 221(6):374-378.","DOI":"10.1055\/s-0029-1239533"},{"key":"65704","doi-asserted-by":"crossref","unstructured":"Thapa N, Pham R, Cole C, Meinershagen M, Bowman PW, Ray A. Therapeutic leukocytapheresis in infants and children with leukemia and hyperleukocytosis: a single institution experience. J Clin Apher. 2018; 33(3):316-323.","DOI":"10.1002\/jca.21610"},{"key":"65705","doi-asserted-by":"crossref","unstructured":"Stahl M, Shallis RM, Wei W. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020; 34(12):3149-3160.","DOI":"10.1038\/s41375-020-0783-3"},{"key":"65706","doi-asserted-by":"crossref","unstructured":"Choi MH, Choe YH, Park Y. The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study. Transfusion. 2018; 58(1):208-216.","DOI":"10.1111\/trf.14329"},{"key":"65707","doi-asserted-by":"crossref","unstructured":"Ganzel C, Becker J, Mintz PD, Lazarus HM, Rowe JM. Hyperleukocytosis, leukostasis and leukapheresis: practice management. Blood Rev. 2012; 26(3):117-122.","DOI":"10.1016\/j.blre.2012.01.003"},{"key":"65708","doi-asserted-by":"crossref","unstructured":"Kittivisuit S, Jongthitinon N, Sripornsawan P. Hyperleukocytosis in childhood acute leukemia: early complications and survival outcomes. Cancers (Basel). 2023; 15(12):3072.","DOI":"10.3390\/cancers15123072"},{"key":"65709","doi-asserted-by":"crossref","unstructured":"Aylan Gelen S, Sarper N, Zengin E, Azizo\u011flu M. Management of hyperleukocytosis in childhood acute leukemia without leukapheresis and rasburicase prophylaxis. J Pediatr Hematol Oncol. 2022; 44(1):12-18.","DOI":"10.1097\/MPH.0000000000002225"},{"key":"65710","doi-asserted-by":"crossref","unstructured":"Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020; 13(5):489-499.","DOI":"10.1080\/17474086.2020.1751609"},{"key":"65711","doi-asserted-by":"crossref","unstructured":"Zhang D, Zhu Y, Jin Y, Kaweme NM, Dong Y. Leukapheresis and hyperleukocytosis, past and future. Int J Gen Med. 2021; 14:3457-3467.","DOI":"10.2147\/IJGM.S321787"},{"key":"65712","doi-asserted-by":"crossref","unstructured":"Takahashi T, Turcotte LM, Gordon PM, Johnson AD, Rubin N, Spector LG. Therapeutic leukapheresis in pediatric leukemia: utilization trend and early outcomes in a US nationwide cohort. J Pediatr Hematol Oncol. 2022; 44(2):47-53.","DOI":"10.1097\/MPH.0000000000002140"},{"key":"65713","doi-asserted-by":"crossref","unstructured":"Christakopoulos GE, Walker KN, Smith J. Clinical characteristics and outcomes of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis managed with different cytoreductive methods. Cancer. 2023; 129(12):1873-1884.","DOI":"10.1002\/cncr.34751"},{"key":"65714","doi-asserted-by":"crossref","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Writing Committee of the American Society for Apheresis: the eighth special issue. J Clin Apher. 2019; 34(3):171-354.","DOI":"10.1002\/jca.21705"},{"key":"65715","doi-asserted-by":"crossref","unstructured":"Thi\u00e9baut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis. Ann Hematol. 2000; 79(9):501-506.","DOI":"10.1007\/s002770000162"},{"key":"65716","doi-asserted-by":"crossref","unstructured":"Porcu P, Danielson CF, Orazi A, Heerema NA, Gabig TG, McCarthy LJ. Therapeutic leukapheresis in hyperleucocytic leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997; 98(2):433-436.","DOI":"10.1046\/j.1365-2141.1997.1943011.x"},{"key":"65717","doi-asserted-by":"crossref","unstructured":"Inaba H, Fan Y, Pounds S. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008; 113(3):522-529.","DOI":"10.1002\/cncr.23581"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285285\/76980","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2024.285285\/77427","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11587\/76980","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:06:23Z","timestamp":1794045983000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2024.285285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,9]]},"references-count":38,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.285285","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,9]]}}}